ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2015
Correlation of histopathologic features of ductal carcinoma in situ of the breast with the oncotype DX DCIS score.
Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Thematic trends and knowledge-map of tumor-infiltrating lymphocytes in breast cancer: a scientometric analysis.Frontiers in oncology · 2024Pooled it
- The impact of immune microenvironment on local control of ductal carcinoma in situ receiving breast conservative therapy.Breast cancer research : BCR · 2026Article
- Decoding tumor-infiltrating lymphocytes heterogeneity in ductal carcinoma in situ: immune microenvironment dynamics and prognostic insights.Discover oncology · 2025Review
- The Microenvironment in DCIS and Its Role in Disease Progression.Advances in experimental medicine and biology · 2025Review
- Personalizing the Treatment of Women with Ductal Carcinoma In Situ (DCIS) Using the DCIS Score: A Qualitative Study on Score Use.Current oncology (Toronto, Ont.) · 2024Article
- Identifying recurrences and metastasis after ductal carcinoma in situ (DCIS) of the breast.Histopathology · 2023Review
- Tumor Infiltrating Lymphocytes in Multi-National Cohorts of Ductal Carcinoma In Situ (DCIS) of Breast.Cancers · 2022Article
- Modulation of the immune microenvironment of high-risk ductal carcinoma in situ by intralesional pembrolizumab injection.NPJ breast cancer · 2021Article
- Unmasking the immune microecology of ductal carcinoma in situ with deep learning.NPJ breast cancer · 2021Article
- Higher density of stromal M2 macrophages in breast ductal carcinoma in situ predicts recurrence.Virchows Archiv : an international journal of pathology · 2020Article
- The prognostic significance of immune microenvironment in breast ductal carcinoma in situ.British journal of cancer · 2020Article
- Prognostic role of immune infiltrates in breast ductal carcinoma in situ.Breast cancer research and treatment · 2019Review
- A whole slide image-based machine learning approach to predict ductal carcinoma in situ (DCIS) recurrence risk.Breast cancer research : BCR · 2019Article
- Ductal carcinoma in situ of the breast: an update for the pathologist in the era of individualized risk assessment and tailored therapies.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2019Review
- Ductal Carcinoma in Situ Biomarkers in a Precision Medicine Era: Current and Future Molecular-Based Testing.The American journal of pathology · 2019Review
- Legumain is an independent predictor for invasive recurrence in breast ductal carcinoma in situ.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2019Article
- Prolyl-4-hydroxylase Α subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS).British journal of cancer · 2018Article
- Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2018Article
- Tumor-infiltrating lymphocytes and ductal carcinoma in situ of the breast: friends or foes?Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2018Review
- Will oncotype DX DCIS testing guide therapy? A single-institution correlation of oncotype DX DCIS results with histopathologic findings and clinical management decisions.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Oncotype DX Breast Cancer Assay for ductal carcinoma in situ is used to determine local recurrence risk in patients with ductal carcinoma in situ. The results help select patients with low-risk ductal carcinoma in situ who could forgo radiation therapy after conservative surgery. The genes assessed include five proliferation genes, progesterone receptor (PR), and GSTM-1. Our objective was to determine if PR, mitotic counting, or any other pathologic feature of ductal carcinoma in situ could predict the Oncotype DX DCIS Score. We identified 46 cases of ductal carcinoma in situ with a Oncotype DX DCIS Score. In addition to information obtained from routine pathology, we counted mitotic figures in the ductal carcinoma in situ and noted presence of dense chronic inflammatory infiltrate surrounding ductal carcinoma in situ. We found that PR ≥ 90% (P = 0.004), mitotic count ≤ 1 (P = 0.045), estrogen receptor ≥ 90% (P = 0.046), and low nuclear grade (P < 0.0001) were associated with a low score. Dense chronic inflammation surrounding ductal carcinoma in situ was associated with a high score (P = 0.034).All 13 cases with PR ≥ 90%, ≤ 1 mitotic figure and absence of dense chronic inflammation around ductal carcinoma in situ had a low score (100% specificity). A low score was not observed in any case with at least two of the following--negative PR, >1 mitotic figure, and/or presence of dense chronic inflammation around ductal carcinoma in situ (100% specificity). Our study suggests using a combination of PR (≥ 90% vs negative) with mitotic count in ductal carcinoma in situ (≤ 1 vs >1) and dense chronic inflammation around ductal carcinoma in situ one could predict the Oncotype DX DCIS score. Mitotic counting and evaluation of immune response might provide prognostic information in ductal carcinoma in situ.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.